Reopening the Case for Reopening the Artery

Key Takeaway: A new critical review of landmark data from the CREST-2 trial reveals that placing a stent in a severely blocked carotid artery—when combined with aggressive medical therapy—significantly lowers the four-year risk of stroke and death compared to medical therapy alone. This analysis suggests that surgical treatment (endarterectomy) would likely show similar benefits with longer follow-up, challenging the growing trend of treating these silent blockages with medication only.

The Silent Danger in Your Neck

Millions of people are entirely unaware they are living with dangerously blocked arteries in their necks. There are no headaches, no dizziness, no warning signs. The carotid arteries, two major blood vessels running up each side of the neck, supply the main blood flow to the brain. When fatty plaques narrow these vessels by 60% or more, the risk of a devastating stroke quietly escalates in the background. For decades, a fierce debate has raged in vascular medicine: Are modern medications alone sufficient to prevent strokes in these asymptomatic patients, or is it necessary to physically reopen the artery itself?

A new critical analysis of two landmark clinical trials suggests the pendulum may have swung too far toward conservative, medication-only management and that many patients deserve more.

What the Research Actually Revealed

At the heart of the analysis are two large randomized controlled trials: CREST-2 and ECST-2. Both were designed to answer the same fundamental question: Does adding a procedure—either placing a small mesh tube called a stent inside the artery or surgically removing the plaque in an operation called a carotid endarterectomy—improve outcomes compared to the best medical therapy alone?

CREST-2 divided its research into two parallel arms. In the stenting arm, patients who received a carotid stent plus intensive medical therapy (IMT) had a significantly lower four-year risk of stroke and death compared to those treated with IMT alone^[1]. This is what researchers call Level I evidence—findings from a well-designed randomized trial, considered the gold standard of clinical medicine.

The surgical arm presented a more nuanced picture. Patients who underwent carotid endarterectomy (CEA) plus IMT showed a trend toward benefit, but the difference did not reach statistical significance within the initial follow-up period. However, the critical analysis makes a compelling argument: this was almost certainly a matter of time, not treatment efficacy. The survival curves had begun to diverge, and the authors contend that with a few more years of data, the combination of CEA and IMT would also demonstrate a statistically significant advantage.

This distinction is critically important. Statistical significance is not the same as clinical insignificance. A treatment can be genuinely effective, but proving its benefit may require a longer observation period—especially in a disease where the risk of a devastating event (stroke) accumulates slowly over years, not weeks.

Why a Blocked Artery Is More Than a Plumbing Problem

To understand why this debate is so heated, one must grasp what is actually happening inside a diseased carotid artery. Atherosclerosis, the process of plaque buildup, is not a simple matter of a clogged pipe. It is an active, inflammatory disease of the artery wall^[2].

Plaques are living structures. They contain a lipid-rich core covered by a fibrous cap, which is infiltrated by immune cells that secrete enzymes that can weaken it over time^[3]. When this cap ruptures, the plaque’s contents are exposed to flowing blood, triggering the formation of a clot. This clot can break off, travel with the bloodstream into the brain, and block a smaller vessel. The result is an ischemic stroke, where brain tissue dies from oxygen deprivation.

Modern intensive medical therapy attacks this process on multiple fronts. High-dose statins stabilize the plaque by reducing inflammation and thickening the fibrous cap^[4]. They also act directly on blood lipids, lowering their levels to help prevent plaque growth. Antiplatelet drugs like aspirin reduce the likelihood of clot formation. Aggressive blood pressure control lowers the mechanical shear stress on vulnerable plaques^[5]. These medications have improved dramatically over the last two decades, which is precisely why some experts have argued that interventional procedures have become obsolete.

But the counterargument, which the analysis forcefully highlights, is this: medications stabilize the plaque, but they do not eliminate it. A severely narrowed artery remains severely narrowed. The hemodynamic compromise, meaning reduced blood flow to the brain, persists. And even stabilized plaques can eventually rupture, especially over the five-, ten-, or fifteen-year time horizons that matter to a 60-year-old patient. Revascularization, whether by stent or surgery, removes the anatomical threat itself.

Reassessing the Need for Intervention

The implications of this analysis are significant. In recent years, there has been a noticeable trend in treatment guidelines for asymptomatic carotid stenosis to favor a medication-only approach, partly due to the increasing effectiveness of drugs and partly due to concerns about procedural complications^[6]. The authors of the analysis push back against this trend, arguing that the CREST-2 stent data now provide Level I evidence that a combined approach—procedure plus intensive medical therapy—is superior to medical therapy alone.

This does not mean every patient found to have a narrowed carotid artery should be rushed to the operating room. Patient selection remains critical. Factors such as the degree of stenosis, the characteristics of the plaque (some may be more ‘vulnerable’ or ‘fragile’ than others), the patient’s overall health and life expectancy, and the experience of the procedural team all play a role. Older studies like ACAS and ACST established the benefit of surgery decades ago, but they were conducted in an era before modern statins and blood pressure drugs were widely used^[7]. CREST-2 is the first major trial to truly test revascularization against contemporary medical therapy, and even in this trial, the stent arm showed a clear victory.

Notable Limitations

No single analysis can rewrite medical practice overnight or supplant established knowledge. The CEA (surgical) arm of the CREST-2 study has not yet shown statistical significance, and until it does, the argument in favor of surgery is based on trend and biological plausibility, not yet on confirmed data. While the follow-up period of four years is meaningful, it is still relatively short for a disease that unfolds over decades. Furthermore, these trials included patients treated by carefully selected and experienced specialists; outcomes in general community practice may differ. Finally, this text is a critical analysis offering an interpretation of existing data, not a new primary research study.

What This Means for Tomorrow’s Patients

If you have been told you have a significant but asymptomatic carotid artery blockage, this analysis could reshape the conversations about your treatment. It is important to remember, however, that this topic remains controversial.

When we review current clinical trials and meta-analyses, it appears that optimized modern medical therapy alone provides similar stroke and mortality outcomes to revascularization for many patients with asymptomatic carotid artery stenosis. Carotid revascularization—particularly stenting in the CREST-2 trial—may offer additional benefit in carefully selected patients with high-grade, high-risk disease, but it also carries procedural risks.

Moreover, ensuring patient adherence to medical therapy is crucial. In clinical practice, we frequently encounter patient fears regarding medication side effects. This can inadvertently influence physicians, making them hesitant to recommend effective drug dosages. Today, physicians have powerful weapons to reverse atherosclerosis. These include: smoking cessation, statins (± ezetimibe/PCSK9 inhibitor), antiplatelet therapy, blood pressure and glucose control, a Mediterranean diet, and exercise^[8].

Nevertheless, every patient’s treatment is unique. In patients with advanced, asymptomatic carotid stenosis, treatment selection must be made with extreme care, and the benefits and risks must be explained in detail. Current guidelines emphasize intensive medical management for all patients and stipulate that revascularization should be decided for select patients based on stenosis severity, imaging features, procedural risk, and life expectancy—ideally through a multidisciplinary, shared decision-making process. I believe this represents the optimal path forward.

Scientific Sources

1. Paraskevas KI, et al. A critical analysis of the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) and the European Carotid Surgery Trial (ECST)-2. Seminars in vascular surgery. 2026;39(2):180-184. PubMed: https://pubmed.ncbi.nlm.nih.gov/42285646/
2. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-874.
3. Virmani R, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262-1275.
4. Crisby M, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Circulation. 2001;103(7):926-933.
5. Cheng C, et al. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation. 2006;113(23):2744-2753.
6. Naylor AR, et al. Editor’s choice—management of atherosclerotic carotid and vertebral artery disease: 2017 clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(1):3-81.
7. Walker MD, et al. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. 1995;273(18):1421-1428.
8. Hackam, D. (2021). Optimal Medical Management of Asymptomatic Carotid Stenosis. Stroke. 2021;52(6):2191-2198.